Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$2.94
-1.3%
$2.47
$1.10
$3.35
$164.52M3.03213,935 shs86,007 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$2.06
-1.2%
$2.90
$1.90
$5.64
$136.72M1.281.41 million shs468,919 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$10.57
+1.1%
$10.91
$4.11
$28.68
$131.39M2.6963,507 shs28,738 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$1.55
+1.6%
$0.79
$0.24
$3.98
$51.35M0.741.22 million shs294,701 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
-2.30%+13.31%+12.03%+124.06%+31.28%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+1.96%-2.35%-14.40%-45.41%-9.96%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-3.95%-4.56%-2.79%-13.48%+47.53%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-5.59%+10.95%+158.50%+117.08%-49.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$2.94
-1.3%
$2.47
$1.10
$3.35
$164.52M3.03213,935 shs86,007 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$2.06
-1.2%
$2.90
$1.90
$5.64
$136.72M1.281.41 million shs468,919 shs
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
$10.57
+1.1%
$10.91
$4.11
$28.68
$131.39M2.6963,507 shs28,738 shs
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
$1.55
+1.6%
$0.79
$0.24
$3.98
$51.35M0.741.22 million shs294,701 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
-2.30%+13.31%+12.03%+124.06%+31.28%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+1.96%-2.35%-14.40%-45.41%-9.96%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-3.95%-4.56%-2.79%-13.48%+47.53%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-5.59%+10.95%+158.50%+117.08%-49.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$4.0036.05% Upside
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.80
Moderate Buy$10.63417.03% Upside
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
3.00
Buy$68.00543.33% Upside
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
2.25
Hold$5.00223.62% Upside

Current Analyst Ratings Breakdown

Latest RLMD, CLLS, CRDF, and FBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$75.00
8/18/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$75.00
8/15/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$61.00
8/6/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$18.00 ➝ $10.00
7/8/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$19.00
6/24/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold$3.50
6/24/2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$61.00
6/18/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectis S.A. stock logo
CLLS
Cellectis
$49.22M3.32N/AN/A$2.36 per share1.25
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$680K201.06N/AN/A$1.86 per share1.10
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/A$8.21 per shareN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/A$1.18 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectis S.A. stock logo
CLLS
Cellectis
-$36.76M-$0.82N/AN/AN/A-100.69%-68.05%-21.53%11/3/2025 (Estimated)
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$79.98M-$2.22N/AN/AN/AN/A-223.17%-180.41%11/6/2025 (Estimated)

Latest RLMD, CLLS, CRDF, and FBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
-$1.21-$0.96+$0.25-$0.96N/AN/A
8/7/2025Q2 2025
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
-$0.25-$0.30-$0.05-$0.30N/AN/A
8/4/2025Q2 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.15-$0.24-$0.09-$0.24$10.07 million$18.19 million
7/29/2025Q2 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/AN/AN/AN/AN/A
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectis S.A. stock logo
CLLS
Cellectis
0.58
1.38
1.38
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
4.42
4.42
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
N/A
11.74
11.74
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
N/A
4.11
4.11

Institutional Ownership

CompanyInstitutional Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
77.63%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
45.24%

Insider Ownership

CompanyInsider Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
7.70%
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
5.90%
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
20.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million61.40 millionOptionable
Forte Biosciences, Inc. stock logo
FBRX
Forte Biosciences
512.43 million11.70 millionOptionable
Relmada Therapeutics, Inc. stock logo
RLMD
Relmada Therapeutics
1033.19 million26.32 millionOptionable

Recent News About These Companies

Relmada Issues Mid-Year CEO Letter to Shareholders
Relmada Therapeutics (NASDAQ:RLMD) Stock Price Up 44.5% - Still a Buy?
Relmada Therapeutics Reports Promising Phase 2 Study Results
RLMD Relmada Therapeutics, Inc. - Seeking Alpha
Relmada Therapeutics, Inc. (RLMD) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cellectis stock logo

Cellectis NASDAQ:CLLS

$2.94 -0.04 (-1.34%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$2.06 -0.03 (-1.20%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Forte Biosciences stock logo

Forte Biosciences NASDAQ:FBRX

$10.57 +0.11 (+1.05%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Relmada Therapeutics stock logo

Relmada Therapeutics NASDAQ:RLMD

$1.54 +0.03 (+1.64%)
As of 03:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.